Robert Ho - 01 Feb 2022 Form 4 Insider Report for Neoleukin Therapeutics, Inc. (NGNE)

Role: Chief Financial Officer
Signature: /s/ Robert Ho
Issuer symbol: NGNE
Transactions as of: 01 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 02 Feb 2022, 15:36:59 UTC
Previous filing: 05 Aug 2021
Next filing: 14 Sep 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NLTX	Restricted Stock Units	Award	$0	+70,000		$0.000000	70,000	01 Feb 2022	Common Stock	70,000	$0.000000	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F2	The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of February 1, 2023 and February 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3	The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney